ERNA · Eterna Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $487.0K | $47.0K | $47.0K | - |
| Cost of Revenue | - | - | - | - | - | - | ($60.0K) | $95.0K | $61.0K | - |
| Gross Profit | - | - | - | - | - | - | $547.0K | ($48.0K) | ($14.0K) | - |
| R&D | $1.92M | - | $1.03M | $1.14M | $1.31M | - | $1.00M | $987.0K | $1.46M | - |
| SG&A | $1.63M | - | $958.0K | $1.36M | $1.42M | - | $3.38M | $3.90M | $4.32M | - |
| Total Operating Expenses | $5.59M | - | $1.99M | $2.50M | $2.73M | - | $2.81M | $4.88M | $5.77M | - |
| D&A | $8.0K | - | $100.0K | $100.0K | $18.0K | - | - | - | $39.0K | - |
| Operating Income | ($5.59M) | - | ($1.99M) | ($2.50M) | ($2.73M) | - | ($2.26M) | ($4.93M) | ($5.79M) | - |
| Interest Expense | - | - | $1.70M | $800.0K | $6.0K | - | - | - | $407.0K | - |
| Income Tax | ($40.0K) | - | $6.0K | $3.0K | $8.0K | - | $12.0K | $3.0K | $4.0K | - |
| Net Income | ($5.51M) | - | ($1.24M) | ($3.14M) | ($8.20M) | - | ($26.60M) | ($5.53M) | ($6.65M) | - |
| EPS - Basic | ($6.95) | - | ($3.75) | ($15.25) | ($56.25) | - | ($1845.00) | ($382.50) | ($461.25) | - |
| EPS - Diluted | ($6.95) | - | ($3.75) | ($15.25) | ($56.25) | - | ($1845.00) | ($382.50) | ($461.25) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.18M | $1.88M | $3.05M | $4.32M | $1.92M | $1.73M | $4.26M | $2.59M | $5.12M | $7.58M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.30M | $1.13M | $958.0K | $1.32M | $1.27M | $1.72M | $2.19M | $2.19M | $2.06M | $1.07M |
| Current Assets | $10.00M | $3.13M | $3.38M | $4.79M | $2.21M | $2.35M | $4.73M | $3.58M | $6.16M | $9.60M |
| Total Assets | $10.54M | $5.83M | $6.17M | $7.58M | $5.06M | $5.27M | $7.72M | $46.49M | $49.66M | $49.13M |
| Current Liabilities | $3.46M | $3.11M | $2.14M | $2.65M | $10.44M | $2.94M | $9.95M | $9.60M | $7.77M | $6.57M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.68M | $3.43M | $2.60M | $3.14M | $11.01M | $3.57M | $53.11M | $55.01M | $53.07M | $46.90M |
| Stockholders' Equity | $6.86M | $2.40M | $3.57M | $4.44M | ($5.95M) | $1.70M | ($45.39M) | ($8.53M) | ($3.41M) | $2.23M |
| Retained Earnings | ($251.14M) | ($245.64M) | ($244.13M) | ($242.88M) | ($239.74M) | ($231.54M) | ($225.77M) | ($199.16M) | ($193.63M) | ($186.98M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.26M) | - | - | - | ($2.06M) | - | - | - | ($3.75M) | - |
| Investing Cash Flow | ($2.0K) | - | - | - | - | - | - | - | ($97.0K) | - |
| Financing Cash Flow | $9.56M | - | - | - | $2.25M | - | - | - | $1.39M | - |
| CapEx | $2.0K | - | - | - | - | - | - | - | $101.0K | - |
| Free Cash Flow | ($2.27M) | - | - | - | - | - | - | - | ($3.85M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 112.3% | -102.1% | -29.8% | - |
| Operating margin | - | - | - | - | - | - | -463.9% | -10491.5% | -12312.8% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -12229.8% | - |
| Net margin | - | - | - | - | - | - | -5462.8% | -11763.8% | -14142.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -8187.2% | - |
| FCF / Net income | 0.41 | - | - | - | - | - | - | - | 0.58 | - |
| R&D / Revenue | - | - | - | - | - | - | 205.5% | 2100.0% | 3102.1% | - |
| SG&A / Revenue | - | - | - | - | - | - | 694.3% | 8289.4% | 9180.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -52.2% | - | -20.1% | -41.4% | -162.1% | - | -344.7% | -11.9% | -13.4% | - |
| Return on equity | -80.3% | - | -34.7% | -70.6% | 137.8% | - | 58.6% | 64.8% | 194.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.89 | 1.01 | 1.58 | 1.81 | 0.21 | 0.80 | 0.48 | 0.37 | 0.79 | 1.46 |
| Quick ratio | 2.89 | 1.01 | 1.58 | 1.81 | 0.21 | 0.80 | 0.48 | 0.37 | 0.79 | 1.46 |
| Cash ratio | 2.65 | 0.61 | 1.42 | 1.63 | 0.18 | 0.59 | 0.43 | 0.27 | 0.66 | 1.15 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -1.2x | -3.1x | -455.0x | - | - | - | -14.2x | - |
| Equity multiplier | 1.54 | 2.43 | 1.73 | 1.71 | -0.85 | 3.10 | -0.17 | -5.45 | -14.55 | 22.00 |
| Liabilities / Assets | 0.35 | 0.59 | 0.42 | 0.41 | 2.18 | 0.68 | 6.88 | 1.18 | 1.07 | 0.95 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.06 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | -13341d | 8426d | 12344d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.6x | - | 63.4x | 53.6x | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | 4374.1x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | -36.1% | -61.0% | -60.4% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -104.8% | - | 11.8% | 49.3% | 52.8% | - | 59.0% | -8.4% | -8.9% | - |
| Net income growth (YoY) | 32.9% | - | 95.3% | 43.2% | -23.4% | - | -375.8% | -22.6% | -22.7% | - |
| EPS growth (YoY) | 87.6% | - | 99.8% | 96.0% | 87.8% | - | -179026.2% | -44900.0% | -43414.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 36.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 41.2% | - | - | -74.4% | -23.8% | - | - | - | -81.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Eterna Therapeutics Inc. against the 5 most active filers in the same SIC group.